From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

被引:190
作者
Wray, Naomi R. [1 ,2 ]
Lin, Tian [1 ]
Austin, Jehannine [3 ,4 ,5 ]
McGrath, John J. [2 ,6 ,7 ]
Hickie, Ian B. [8 ,9 ]
Murray, Graham K. [1 ,9 ,10 ]
Visscher, Peter M. [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4067, Australia
[2] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia
[3] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[5] BC Mental Hlth & Subst Use Serv Res Inst, Vancouver, BC, Canada
[6] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Wacol, Qld, Australia
[7] Aarhus Univ, Natl Ctr Register Based Res, Aarhus, Denmark
[8] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[9] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England
[10] Univ Cambridge, Dept Psychiat, Cambridge, England
基金
英国医学研究理事会; 新加坡国家研究基金会; 澳大利亚研究理事会;
关键词
CORONARY-ARTERY-DISEASE; PREDICTIVE ACCURACY; GENETIC RISK; HERITABILITY; PSYCHIATRY;
D O I
10.1001/jamapsychiatry.2020.3049
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Importance Polygenic risk scores (PRS) are predictors of the genetic susceptibilities of individuals to diseases. All individuals have DNA risk variants for all common diseases, but genetic susceptibility differences between people reflect the cumulative burden of these. Polygenic risk scores for an individual are calculated as weighted counts of thousands of risk variants that they carry, where the risk variants and their weights have been identified in genome-wide association studies. Here, we review the underlying basic science of PRS, providing a foundation for understanding the potential clinical utility and limitations of PRS. Observations Polygenic risk scores can be calculated for a wide range of diseases from a saliva or blood sample using genotyping technologies that are inexpensive. While genotyping only needs to be done once for each individual in their lifetime, the PRS can be recalculated as identification of risk variants improves. On their own, PRS will never be able to establish or definitively predict future diagnoses of common complex conditions because genetic factors only contribute part of the risk, and PRS will only ever capture part of the genetic contributions. Nonetheless, just as clinical medicine uses a multitude of other predictive measures, PRS either on their own or as part of multivariable predictive algorithms could play a role. Conclusions and Relevance Utility of PRS in clinical medicine and ethical issues related to their use should be evaluated in the context of realistic expectations of what PRS can and cannot deliver. For different diseases, PRS could have utility in community settings (stratification to better triage people into established screening programs) or could contribute to clinical decision-making for those presenting with symptoms but where formal diagnosis is unclear. In principle, PRS could contribute to treatment choices, but more data are needed to allow development of PRS in this context. This review provides a foundation for understanding the basic science as well as the potential clinical utility and limitations of polygenic risk scores.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 49 条
  • [1] Alliance NVDP, 2020, AUSTR ABS CARD DIS C
  • [2] [Anonymous], 1998, GENETICS ANAL QUANTI
  • [3] Evidence-Based Genetic Counseling for Psychiatric Disorders: A Road Map
    Austin, Jehannine C.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2020, 10 (06):
  • [4] Mammography screening: A major issue in medicine
    Autier, Philippe
    Boniol, Mathieu
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 90 : 34 - 62
  • [5] Baselmans BML, 2020, BIOL PSYCHIAT
  • [6] Interdisciplinary psychosocial care for families with inherited cardiovascular diseases
    Caleshu, Colleen
    Kasparian, Nadine A.
    Edwards, Katharine S.
    Yeates, Laura
    Semsarian, Christopher
    Perez, Marco
    Ashley, Euan
    Turner, Christian J.
    Knowles, Joshua W.
    Ingles, Jodie
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (07) : 647 - 653
  • [7] Developing and evaluating polygenic risk prediction models for stratified disease prevention
    Chatterjee, Nilanjan
    Shi, Jianxin
    Garcia-Closas, Montserrat
    [J]. NATURE REVIEWS GENETICS, 2016, 17 (07) : 392 - 406
  • [8] Tutorial: a guide to performing polygenic risk score analyses
    Choi, Shing Wan
    Mak, Timothy Shin-Heng
    O'Reilly, Paul F.
    [J]. NATURE PROTOCOLS, 2020, 15 (09) : 2759 - 2772
  • [9] Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score
    Desikan, Rahul S.
    Fan, Chun Chieh
    Wang, Yunpeng
    Schork, Andrew J.
    Cabra, Howard J., I
    Cupples, L. Adrienne
    Thompson, Wesley K.
    Besser, Lilah
    Kukull, Walter A.
    Holland, Dominic
    Chen, Chi-Hua
    Brewer, James B.
    Karow, David S.
    Kauppi, Karolina
    Witoelar, Aree
    Karch, Celeste M.
    Bonham, Luke W.
    Yokoyama, Jennifer S.
    Rosen, Howard J.
    Miller, Bruce L.
    Dillon, William P.
    Wilson, David M.
    Hess, Christopher P.
    Pericak-Vance, Margaret
    Haines, Jonathan L.
    Farrer, Lindsay A.
    Mayeux, Richard
    Hardy, John
    Goate, Alison M.
    Hyman, Bradley T.
    Schellenberg, Gerard D.
    McEvoy, Linda K.
    Andreassen, Ole A.
    Dale, Anders M.
    [J]. PLOS MEDICINE, 2017, 14 (03):
  • [10] Donnelly P, USING GENOMICS UNDER